CD274 and neoplasm: A 2022 study found that sequential therapy with pembrolizumab-lenvatinib-TACE may have promising anti-tumor activity, an acceptable conversion rate, and a well-characterized safety profile in patients with uHCC who were initially PD-L1 positive [16].